Research Library › GHRH & Ghrelin-Receptor
MGF, or mechano growth factor, is a splice variant of insulin-like growth factor 1 (IGF-1) that shares IGF-1’s core sequence but carries a different C-terminal tail. It was identified in 1996 by Geoffrey Goldspink’s laboratory at the Royal Free Hospital School of Medicine in London. PEG-MGF is MGF with polyethylene glycol (PEG) attached. As of 22 Oct 2026 neither is FDA-approved; FDA advisers are scheduled to review PEG-MGF before the end of February 2027.
Key facts
| Type | IGF-1 splice variant (MGF); PEGylated form (PEG-MGF) |
|---|---|
| Derived from | The IGF-1 gene, via alternative splicing that changes the C-terminal E-peptide |
| First described | 1996, Goldspink laboratory (Yang et al., Journal of Muscle Research and Cell Motility) |
| Developed by | Geoffrey Goldspink and colleagues, Royal Free Hospital School of Medicine, London |
| Designed target | Proposed local autocrine signaling, distinct from liver-derived IGF-1 (unproven in humans) |
| Regulatory status (Oct 2026) | Not FDA-approved; PEG-MGF removed from FDA Category 2 in April 2026, PCAC review due by Feb 2027; named on WADA 2026 list (S2) |
Who developed it
MGF was identified in the laboratory of Geoffrey Goldspink at the Royal Free Hospital School of Medicine in London. A 1996 paper by S. Yang, Goldspink and colleagues reported cloning and characterizing the IGF-1 isoform from rabbit skeletal muscle tissue subjected to stretch [1]. Goldspink later gave it the name “mechano growth factor” to distinguish it from the IGF-1 produced by the liver [2].
What it was designed to target
The IGF-1 gene can be spliced in more than one way, producing proteins that share the same mature IGF-1 sequence but end in different C-terminal extensions, called E-peptides. MGF is the variant with a distinct E-peptide, which sets it apart from the circulating form of IGF-1 [1].
Goldspink proposed that MGF acts as a locally produced, autocrine signal, made in tissue in response to mechanical stimulus rather than released into the blood by the liver [2]. That role remains a proposal; it has not been established in humans.
PEG-MGF is MGF with polyethylene glycol chains attached, a modification commonly used in peptide research to slow clearance [3].
Why it was created
MGF was not designed as a drug. It emerged from basic research asking how tissue responds locally to mechanical load, and whether growth factors made in the tissue itself differ from the systemic IGF-1 controlled by growth hormone [1][2]. PEG-MGF is a later synthetic derivative that was nominated for pharmacy compounding in the United States; that nomination was subsequently withdrawn [3].
Research timeline
- 1996: Goldspink’s laboratory clones the IGF-1 isoform later called MGF [1].
- 1999: Goldspink describes MGF as a locally expressed growth factor distinct from liver IGF-1 [2].
- Apr 2026: FDA moves PEG-MGF off its Category 2 list [4].
- By Feb 2027: FDA’s Pharmacy Compounding Advisory Committee is scheduled to review PEG-MGF [5].
Regulatory status as of October 2026
As of 22 Oct 2026, neither MGF nor PEG-MGF is FDA-approved, and no approval elsewhere has been identified. FDA states that it found no human exposure data for PEG-MGF and flags a possible risk of immune reactions [3].
In April 2026 FDA removed PEG-MGF from Category 2, its list of bulk substances that may present significant safety risks in compounding. Removal does not by itself permit compounding [4]. FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review PEG-MGF, along with LL-37, GHK-Cu and others, at a meeting before the end of February 2027 [5]. Separately, on 14 Oct 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its text and peptide list are not public [6].
Mechano growth factors are named on the 2026 World Anti-Doping Agency Prohibited List under S2, prohibited at all times [7].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is MGF?
MGF (mechano growth factor) is a splice variant of IGF-1 with a distinct C-terminal E-peptide, first characterized in 1996 by Geoffrey Goldspink’s laboratory in London.
What is the difference between MGF and PEG-MGF?
PEG-MGF is MGF with polyethylene glycol (PEG) attached, a chemical modification commonly used to slow a peptide’s clearance.
Is PEG-MGF FDA approved?
No. As of 22 Oct 2026 PEG-MGF is not FDA-approved. FDA removed it from its Category 2 list in April 2026, and its advisory committee is scheduled to review it before the end of February 2027.
Who discovered mechano growth factor?
Geoffrey Goldspink and colleagues at the Royal Free Hospital School of Medicine, London, identified it in 1996 and later named it mechano growth factor.
Sources
- Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and characterization of an IGF-1 isoform expressed in skeletal muscle subjected to stretch. J Muscle Res Cell Motil. 1996;17(4):487–495. doi:10.1007/BF00123364. Link
- Goldspink G. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. J Anat. 1999;194(Pt 3):323–334. doi:10.1046/j.1469-7580.1999.19430323.x. PMID 10386770. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- U.S. FDA. Meeting of the Pharmacy Compounding Advisory Committee (before end of February 2027; LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF). Link
- Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
- World Anti-Doping Agency. 2026 Prohibited List (S2.2.4 growth hormone releasing factors; S2.3 growth factors). In force 1 Jan 2026. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
